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Stroke is the second leading cause of death and  third leading cause of disability worldwide 
and its burden is increasing rapidly in low- and middle-income countries (LMICs), many of 
which are unable to face the challenges it imposes. In this Policy View paper on primary stroke 
prevention, we provide an overview of the current situation regarding primary prevention 
services, cost of stroke and stroke prevention, and identify deficiencies in existing guidelines 
and gaps in primary prevention. We further offer a set of pragmatic solutions for 
implementation of primary stroke prevention, with an emphasis on population-wide 
strategies, including task shifting/sharing and health system re-engineering that includes 
patients, health professionals, funders, policymakers, implementation partners and the entire 
population along the life course.  
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Introduction  
The burden of stroke remains a huge public health issue of growing importance. In 2019, 
stroke was the second leading cause of death (6.6 million) and disability (143 million disability-
adjusted life years lost [DALYs]) worldwide, after neonatal disorders (in children) and 
ischaemic heart disease (in adults).1 Over the past three decades,  global stroke incidence 
increased by 70%, its prevalence by 85%, its mortality by 43%, and  DALYs due to stroke by 
32%, with a greater increase in stroke burden in low- and middle-income countries (LMICs)   
compared to high-income countries (HICs).  Over a similar time frame, from 1990 to 2018, 
there was a 37% global increase in the total number of stroke-related DALYs due to risk 
factors, with LMICs disproportionately affected. Indeed, LMICs experienced a 48% increase in 
stroke-related DALYs attributable to risk factors, while in HICs there was a 25% decline.1 In 
2019,  the five leading risk factors were high systolic blood pressure, high body-mass index, 
high fasting plasma glucose, ambient particulate matter (PM2.5) pollution, and smoking (figure 
1).1 
In 2011, the United Nations (UN) resolution followed by the WHO Global Action plan 2013-
2020 called upon all governments to give primary prevention of non-communicable diseases 
(NCDs), including stroke, the highest priority. The goal was to achieve a 25% reduction in their 
NCD-related burden by 2025.2,3 However, as stated by the UN Secretary-General in 2017,4 the 
current level of progress on the prevention and control of NCDs is insufficient to meet the 
goal. The already enormous and continuously growing burden of stroke presents several 
challenges. First, although LMICs bear most of the burden, they have only a small share of the 
global financial and health-care resources to combat it. Over 90% of the poorest billion people 
live in LICs and lower-MICs.5 Secondly, strokes occur about 15 years earlier among individuals 
in LMICs than in HICs6 leading to a marked negative impact on socio-economic development, 
as persons at the peak of their productive lives are most often affected.7 Finally, despite the 
current available knowledge of evidence-based interventions for stroke prevention, this has 
not been translated into reduced stroke burden in LMICs due to barriers limiting 
implementation.8  
The growing burden of stroke across the globe strongly suggests that current primary stroke 
and cardiovascular disease (CVD) prevention strategies are either not used widely enough or 
are insufficiently effective. A previous comprehensive review of  primary and secondary 
prevention of stroke9 was largely focused on individual risk factors and measurements of the 
effectiveness of preventative interventions. This Policy View paper is based on a more holistic 
approach including a critical review of existing primary prevention strategies and current 
guidelines, economic analysis, and identification of gaps in primary stroke prevention. This 
approach enabled us to provide evidence-based pragmatic solutions on strategies for primary 
stroke prevention within a cost framework that global, regional and national policymakers 
can use to reduce the burden of stroke across the globe, especially in LMICs (Panel 1). To 
derive these solutions (figure 2) the following four steps were carried out. Firstly, a situational 
evaluation was conducted by collecting and analysing data on the state of stroke-related 
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services and resources in LMICs compared to HICs.10  Secondly, priority setting was conducted 
by extracting the highest grade of evidence-based recommendations using the stroke 
guidelines that best satisfied the criteria from the Institute of Medicine11 as identified from a 
systematic review of all available stroke guidelines across the globe. Thirdly, the barriers and 
facilitators for implementing these recommendations in the context of LMICs were derived 
from the situational evaluation and relevant literature review (Tables 1 and 2). Finally, a 
roadmap for primary prevention was devised (Tables 1 and 2) and pragmatic solutions were 
proffered to implement evidence-based recommendations to reduce the burden of stroke in 
LMICs and other underserved settings. 
 
The cost burden of stroke and the economic case for prevention  
To develop an economic case for the pragmatic solutions we are proposing for the primary 
prevention of stroke, we performed an economic analysis based on simulation modelling. We 
estimated the global financial costs of providing acute care to patients with stroke in hospital 
including rehabilitation, as well as associated income losses due to premature death and 
disability as a result of stroke (supplementary materials section 1). In brief, data from the GBD 
study on the number of new stroke cases and deaths from stroke in 201712 were combined 
with best available estimates of the costs of stroke treatment and rehabilitation from a 
selected number of countries respresenting different income-levels (i.e. Germany, United 
States, United Kingdom, Japan, China, Brazil, Turkey and India). Our estimates suggest that 
stroke-related treatment and rehabilitation costs globally ranged from approximately US$66 
billion to US$213 billion among new stroke cases in 2017. In addition to direct costs, there 
were large indirect costs associated with income losses from premature death and disability 
after stroke. We estimated that the discounted lifetime economic losses to households with 
incident stroke cases in 2017 amounted to US$576 billion globally. Roughly half of the global 
income losses from stroke occurred in HICs, and another 42% in upper-MICs. Income losses 
from stroke in LMICs and LICs accounted for only 8% of the global total, primarily because of 
their much lower income levels. Thus, based on our simulation modelling, the estimated 
treatment, rehabilitation, and indirect costs for stroke are more than US$700 billion annually. 
A linear interpolation shows that if the current trends in stroke burden continue, by 2030 the 
cost of stroke to the global economy will be over US$1 trillion. These estimates are likely to 
be conservative because they do not account for out-of-pocket costs and income losses 
arising from the added responsibilities falling upon caregivers who may have to give up paid 
work.  
Even so, with the costs of stroke care, the economic gains from interventions that can help 
reduce stroke incidence and/or mortality by small numbers are potentially very large. There 
is a sufficient body of evidence to show that achieving the United Nations (UN) Sustainable 
Development Goals (SDGs)13 (supplement section 2) and WHO health targets3 with low costs, 
e.g. <US$1 a day (US$0.43-US$0.90) across low-income countries and <US$3 a day (US$0.54-
US$2.93) across middle-income countries,14,15  could reduce the mortality rate for ischaemic 
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heart disease and stroke by 10%. In turn, economic losses in LMICs would be reduced by an 
estimated US$25 billion per year.15,16 Another promising strategy is to re-prioritise health 
investment streams towards population-wide primary prevention across the lifespan. It has 
been estimated that for every US$1 spent on prevention of stroke and CVD there is over 
US$10 return on investment, and that the preventative interventions focused on risk factors 
are the most cost-effective options.17 Moreover, stroke primary prevention efforts are likely 
to yield  large gains due to spill over effects in terms of reducing the risk of acquiring heart 
disease, type 2 diabetes mellitus, dementia and some types of cancer that share common risk 
factors, thus supporting achievements of a range of the UN SDGs.  
Epidemiological evidence and situational analyses for improving primary prevention 
Our recent World Stroke Organization (WSO) coordinated international survey on stroke10,11 
showed that only about one-third of the recommended primary prevention activities are 
being used in the 82 countries participating in the survey, and these activities were 
particularly poor in LICs. Although more than three quarters (81%) of countries reported that 
CVD risk stratification was offered at primary health care facilities, the availability reported 
within these countries varied widely. While nearly half of these countries reported that risk 
stratification was available in over 50% of health care facilities, 29% reported that it was 
available in fewer than 25% of facilities, and an additional 15% reported that it was available 
in between 25% and 50% of facilities. Moreover, just over half of the countries (53%) reported 
general availability of all six essential tests and procedures (measurement of height, weight, 
blood pressure, blood glucose, and total cholesterol, as well as urine strips for albumin assay). 
Marked disparities were evident across the income groups: 96% of HIC reported all six tests 
and procedures were generally available compared with 16% of low-income countries. 
Although many countries have a national strategy towards a healthy diet, reducing tobacco 
use and reducing diabetes, only 42% of countries have national strategies for all three issues, 
and less than 1 in 3 countries have smoke-free environments in all indoor workplaces, public 
transport and indoor public places.  
There are two main primary stroke/CVD prevention strategies currently in use: population-
wide and individual high CVD risk strategies. Conventional screening of the population for 
high CVD risk using various prediction algorithms (such as Atherosclerotic Cardiovascular 
Disease [ASCVD] Risk Evaluation18 or PREDICT algorithms19), which categorise people into 
mild (moderate), low or high CVD risk. These have been shown to be ineffective to reduce 
stroke and ischaemic heart disease incidence and mortality rates in randomised trials in 107 
421 persons (relative risk, 1.05 [95% CI, 0.95–1.17]; I2=53%).20-22 Because of the need for a 
blood lipid test, and associated costs, these prediction tools have low applicability in LMIC 
settings23 (until low-cost point of care devices are available for blood lipid testing). Moreover, 
as stated by the World Heart Federation and WSO24 these screening programmes may 
exacerbate socioeconomic inequalities,25 have potential hazards of labelling people as ‘low 
risk’, giving them false reassurance that they are protected from stroke and heart attack and 
compromising any motivation to control risk factors.23,25 Therefore, it has been suggested 
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that when communicating absolute CVD risk to patients, categorisation of people into low, 
moderate (mild) and high risk (including heat charts) should be abandoned.24,26 Finally, “high-
risk” prevention strategies are targeted rescue operations for high CVD risk individuals that 
are usually implemented by health care professionals. Whilst they may be adequate for 
conditions confined to an identifiable minority of people at high CVD risk, stroke/CVD is a 
disease of society,27 and most cases (up to 80%) arise in “low risk” individuals,28,29 not covered 
by the high-risk prevention strategies.23 Issues for clinicians in primary stroke prevention at 
the individual level include the lack of digital decision-making tools,30 and the lack of time to 
motivate, develop and  give  tailored primary prevention recommendations to the patient. An 
example of a digital decision-making tool that can help to solve all these issues is the desk-
top multi-language PreventS© webapp for clinicians.1 The PreventS© webapp can be 
integrated with  electronic medical databases via a cloud-based agnostic system that 
clinicians can securely use on any computer (figure 3, supplement section 3).  
As the mean (average) level of exposure to causal risk factors throughout the population 
correlates closely with the incidence of stroke/CVD in the population, the population-based 
strategy of prevention aims to reduce the mean level, and overall distribution, of exposure to 
causal risk factors throughout the population to reduce the incidence of CVD.31 Preliminary 
calculations suggest that if population-wide strategies were implemented widely and 
effectively they could prevent up to 50-90% of stroke/CVD events over 5 years.1,26,32,33 A 
motivational mass prevention strategy via eHealth technologies34 in combination with polypill 
and task-shifting/sharing (or task-transfer)26 could prevent up to 50% of stroke/CVD events. 
“High risk” strategies can potentially prevent about 11% of stroke/CVD events (figure 4),35 
with both strategies complementing each other36,37 and priority given to population-wide 
strategies.23,24  
Guidelines and pragmatic solutions 
Population-wide strategies for primary stroke/CVD prevention are well established3 (e.g. 
nation-wide measures to reduce exposure to smoking/vaping, sugary drinks, excessive salt 
and alcohol intake; promote adequate physical activity etc.). They are recommended in 
several international and WHO guidelines,14,38-40 but their implementation in practice is 
unacceptably slow and far from universal.11 As shown in a recent systematic review of stroke 
guidelines,11 there are two main reasons for slow implementation of population-wide 
strategies. First, such strategies require policy and legislative changes that are often not 
supported by major industries (e.g., salt reduction in processed food, reduction of exposure 
to smoking, alcohol, fast food).41 Second, implementation of a full range of population-wide 
prevention strategies requires substantial investments from governments and industry, 
preferably creation of the Universal Health Coverage, including setting up affordable and 
widely accessible health services, affordable facilities for adequate physical activities to 
integrate physical activity into our daily lives, reduction of air pollution and socio-economic 
inequalities. In addition, despite a special 2011 NCDs UN Declaration to have a NCD 
prevention plan in every country,2 most countries still do not have such a plan.  
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The majority of the burden of stroke (60-70%) across all countries in the world is associated 
with elevated systolic blood pressure (SBP) and unhealthy lifestyle risk factors such as 
smoking, obesity, low physical activity and poor diet (including excessive salt, sugar and 
alcohol intake; low fruits/vegetables consumption).1 Reducing exposure to these risk factors 
and treating hypertension should be the priority targets for both population-wide and 
individual-based preventative interventions for primary stroke prevention (panel 2). A good 
example of decisive actions to stop smoking is the recent suite of proposals of the New 
Zealand government aimed at creating a smoke free generation and moving the country 
closer to its goal of being smoke-free by 2025. Step-by-step action plans and online courses 
on Global Salt Reduction Strategies for policy makers, advocates, and programme managers 
have recently been developed to implement scalable sodium reduction interventions 
focusing mainly on LMICs, and are offered for free by Johns Hopkins University. The medical 
community must continue to lobby and advocate governments to implement evidence-based 
population-wide prevention strategies. 
Based on the totality of evidence the WSO recently issued a Declaration26 that recommends 
the use of the following four strategies for global primary prevention of stroke and dementia: 
(1) population-wide policy strategies to reduce exposure to risk factors for stroke, dementia, 
CVD and other NCDs (including environmental risk factors such as air pollution) across the 
lifespan of the entire population regardless of the level of individual CVD risk; (2) motivational 
population-wide strategy using health apps (an example is the free Stroke Riskometer 
app22,34,42,43 ) or similar mobile phone applications to reduce lifestyle and other risk factors in 
adults at any increased risk of stroke (supplementary section 3, figure 1); (3) targeted polypill 
(consisting of two low-dose generic blood pressure and one generic lipid lowering 
medication) strategy for middle-age and older adults at risk of CVD (at least two behavioural 
and/or metabolic CVD risk factors); and (4) preventative strategies to control behavioural risk 
factors (especially smoking, elevated blood pressure) and diabetes mellitus via community 
health workers (community health workers were also suggested to facilitate implementation 
of strategies 2 and 3).  
As stated in the WSO Declaration,26 policy makers and health providers must reduce exposure 
to risk factors at a population level regardless of the CVD risk through mass approaches (e.g. 
smoking cessation campaigns, reducing salt and sugar in  processed food and restricting 
alcohol consumption) and more individual-focused motivational education about behavioural 
risks (poor diet, physical inactivity, alcohol and smoking) via the free Stroke Riskometer app 
or similar mobile phone applications would apply to the general population at any risk of CVD. 
In addition, simple inexpensive screening for vascular risks (elevated blood pressure, smoking 
and overweight/obesity)22 by community health workers or people from stroke support 
organisations in resource poor settings or by medical professionals (including blood lipid 
tests) in more affluent countries, would identify individuals in need of prophylactic drug 
therapy, in conjunction with lifestyle and behavioural interventions.23 There is also evidence  
of sex differences in the risk of stroke1 and its risk factors44 and that the intensity of primary 
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stroke prevention should not be reduced in older people.45 These recommendations are 
summarised in the 2021-2030 Primary Stroke Prevention Roadmap (Table 1). With all these 
recommendations implemented into practice, a similar risk factor shift in the distribution of 
risk factors would occur as with the population-wide primary prevention strategy (figure 4, 
part A). 
Joint efforts and establishment of a regional and national plans 
Stroke is a complex medical and socioeconomic issue. Therefore the importance of global, 
international and national efforts and collaboration between various sectors of health care 
and decision-makers, government and non-government agencies (e.g. stroke and CVD/NCD 
organisations), industry, communities and individuals for effective reduction of stroke burden 
cannot be overemphasised (figure 5).9,46 Government bodies have the power and 
responsibility to provide adequate health services to cover primary prevention, improve 
socioeconomic conditions, reduce inequities and influence environmental (e.g. reduction of 
air pollution, building healthy cities) and lifestyle factors (e.g. reducing salt, sugar in processed 
food and alcohol intake through legislation and taxation). In concert with this, health systems 
have responsibilities for identification and management of risk factors and people with 
cerebrovascular diseases, and government and non-government organisations have 
responsibilities for ongoing public (e.g., stroke awareness days) and professional education 
(e.g. teaching courses, conferences). In addition, intersectoral intervention is required to 
provide essential medicines for primary stroke prevention (e.g., affordable blood pressure 
and lipid lowering medications) and an enabling environment for healthy lifestyles, including 
reworking the food chain to make healthy food available and affordable for all, providing safe 
neighbourhoods conducive to walking, and ensuring access to care. Another approach would 
be to change public policy to enable community health workers to distribute  medicines 
prescribed by doctors. This is particularly important in hard-to-reach regions where there is 
limited access to medical professionals. This type of coordinated intervention allows 
interlinking community-wide prevention and individual management approaches that 
improve health across the care continuum, and across settings and strategies (figure 5).47  
The development and implementation of action plans for primary stroke prevention should 
be aimed towards achieving the internationally recommended goals and targets for reducing 
the burden from NCDs.2,3 These country-specific and financially sustainable action plans and 
consensus statements need to be (i) developed by recognised local experts, (ii)  evidence-
based, (iii) endorsed by government agencies, and (iv) contain well-developed 
implementation plans including key performance indicators, steps, timelines, funding 
(including funding for implementation) and accountable people. These action plans must be 
facilitated by national, culturally appropriate, and up-to-date guidelines for primary stroke 
prevention. Unfortunately, there is a shortage of operational national plans aligned with the 
Global Action Plan on NCDs.48 While there are a number of national guidelines for primary 
stroke prevention in HICs,38,49 there is a paucity of such evidence-based, context-appropriate 
pragmatic guidelines in LMICs.9  
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Although mainstream preventative strategies should be similar in HICs and LMICs, differences 
in the population-attributable risks, lifetime risk of stroke, the distrubtuion of different risk 
factors and the availability of resources should be considered when setting goals and 
priorities. For example, given the much greater burden of smoking, air pollution and 
haemorrhagic stroke in LMIC than in HIC, a strong emphasis on early detection and 
management of elevated blood pressure, reduction of air pollution and anti-smoking 
campaigns should be a priority in LMICs. This should be facilitated by government-imposed 
measures to reduce sodium in  processed food as well as education of individuals about 
reducing salt and tobacco intake.50 In addition, in HICs, where smoking prevalence has 
reduced and the burden associated with ischaemic stroke is noticeably higher than in LMICs, 
it seems reasonable to focus more heavily on reduction of other behavioural risks (particularly 
on the reduction of sugar consumption and physical inactivity) as well as on the identification 
and pharmacological or surgical management of medical conditions that lead to stroke, 
including hypertension, diabetes mellitus and atrial fibrillation. Population-wide and 
individual primary stroke/CVD prevention strategies (including motivational mass individual 
strategy)42 should be used regardless of the level of stroke/CVD risk, with  priority given to 
population-wide strategies.  
Actions to improve stroke prevention come at a cost. With already overstretched health 
budgets, even in HICs, one wonders where the funding could come from to support stroke 
prevention in a sustainable manner. One of the most promising strategies to secure such 
funding is to re-invest revenues from taxation on unhealthy products (e.g. tobacco, sugary 
drinks, alcohol, salt in processed food)17,51-56 followed by adding savings from preventing 
stroke back into health services and preventative strategies.47 This is important as reduced 
consumption of these unhealthy foods has been shown to be beneficial for stroke/CVD and 
overall health at the population level. Although it is widely acknowledged that prevention is 
better than cure, even high-income countries allocate less than 2-3% on average of their 
health spending to public health and prevention activities57 and there is also evidence of 
significant underfunding of stroke-related research.58 Governments have to be transparent 
about the proportion of health budgets that are focused on prevention. 
Politicians and policy decision-makers must realise that without urgent improvement in 
primary prevention of stroke and other major NCDs, the sustainability of the whole health 
system will soon be in question. Only by joining forces with other interventions for NCD 
prevention will stroke prevention have its full impact.46 The Global Alliance for Chronic 
Diseases59 is a good example of such an integrative approach. There are several reports 
showing the effectiveness of population-wide primary prevention strategies in selected 
populations of Finland,60 Japan61 and the USA.62  
Innovative dissemination for substantial implementation and impact 
Beyond the publication of these key recommendations and evidence-based pragmatic 
solutions and advocacy tools, further steps will be taken immediately by the commissioners, 
the WHO and the WSO to spread the key messages of this Commission, through innovative 
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deployment via social media and other media platforms. This will include engagement of 
societal opinion-shapers via the establishment of the Global Stroke Control, Observatory and 
Reduction Ecosystem (gSCORE, supplement section 4, figure 2)10,63 to: (i) address key 
environmental factors via policy change – social determinants of health, making default 
choices healthy; (ii) enhance stroke literacy through key community influencers who can 
deliver culturally tailored messages, using strategies such as social media (social media 
influencers with impact), the arts (music, comedy, film, TV); (iii) address motivation, self-
efficacy, self-management skills; and (iv)  empower the stroke commissioners to be the 
champions and advocates ensuring rigorous implementation and evaluation across the globe. 
The gSCORE, leveraging the WHO Global Action plan against NCDs, is planned to operate at 
country, regional and global levels in collaboration with relevant policy makers and 
implementation partners including national and regional stroke, neurology, CVD and NCD 
organisations and relevant alliances.  
 
Conclusions and future directions  
The proffered key solutions are targeted at reducing the occurrence of stroke and preventing 
economic losses from stroke through primary prevention across the life-course. As many 
lifestyle habits are set early in life, culturally appropriate education about healthy lifestyles 
should be incorporated into standard education curricula, started early in life with 
reinforcement across the lifespan and incorporate families. These preventative strategies 
should be complemented by adequate stroke education campaigns that consider cultural and 
subcultural differences and beliefs of people of various races and ethnicities but also 
significant geographical differences in the lifetime risk of stroke and its risk factors.  
For an effective effort, there is a need for synergy between healthcare providers, government 
and non-government agencies, industry, academic organisations, societal opinion-leaders, 
and individuals. An approach which integrates strategies aimed at primary stroke prevention 
(population-wide and targeted strategies towards individuals with any level of increased 
stroke risk) with strategies aimed at prevention of other NCDs is most likely to be successful, 
as many risk factors are shared between stroke and other NCDs.  
As many stroke risk factors are common to other major NCDs, such as ischaemic heart 
disease, type 2 diabetes mellitus, renal disease, dementia, and some types of cancer, it is 
expected that the worldwide implementation of the solutions will not only halve the burden 
of stroke but also significantly reduce the burden from other major NCDs. This would not only 
save millions of lives around the globe but would also have a dramatic economic impact. 
Developing primary stroke prevention guidelines for LMIC is urgently required. We must 
increase the target audience for future primary stroke prevention guidelines in both HIC and 
LMIC since many primary stroke prevention interventions require intersectoral funding and 
policy initiatives as well as population buy-in. Further research is required to develop 
integrative, culturally appropriate, and population-specific eHealth technologies for effective 
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primary stroke prevention, including digital decision-making tools for clinicians and 
community health workers, and to establish the best balance between various primary stroke 
prevention strategies to maximise cost effectiveness and minimise inequalities. 
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Panel 1. Aims of this Policy View 
• To provide an understanding of the burden and cost of stroke, and evidence for cost 
and cost-effectiveness of the existing primary stroke prevention strategies  
• To provide an overview of available primary stroke prevention strategies, services, 
guidelines, and identify deficiencies and gaps in primary stroke prevention  
• To provide a set of pragmatic solutions for policy makers, funding organisations and 
other stakeholder for funding and implementation of primary stroke prevention 
strategies, with examples of successful translation of evidence into actions 
 
Search and selection criteria 
For covering the latest data, we searched MEDLINE, Embase, Google Scholar, and the 
Cochrane Library, as well as the internet (using Google and other search engines), for 
research published between January 1980 and 15 May 2021 using the following key words 
in title or abstract: “stroke”, “cerebrovascular disease”, “isch(a)emic stroke”, “intracerebral 
h(a)emorrhage”, “subarachnoid h(a)emorrhage” “transient isch(a)emic attack” or 
“cardiovascular disease AND “prevention”, “cost”, “guidelines”, “awareness”, “tax or 
taxation”, “trial”, “policy”, “legislation”, “mHealth”, “eHealth”, “polypill”, “roadmap”, 
“incidence”, “prevalence”, “mortality”, “burden” or “outcomes”. Also, websites of medical 
societies and stroke experts were approached for additional stroke prevention guidelines. 
We concentrated on population-based studies and guidelines related to primary stroke 
prevention since 2011. Additionally, we manually searched the reference lists of relevant 
publications and consulted with experts in stroke, CVD and other relevant stakeholders, to 







Panel 2. Key solutions for primary stroke prevention 
• Effective stroke prevention must include both population-wide and individual-based strategies 
that cover all or most of the population, with priority given to population-wide strategies. 
Individual-based primary stroke prevention strategies can be best accomplished using:  
o Mobile technology (so-called motivational mass individual strategy for stroke 
prevention),23 a simple, inexpensive screening for a history of CVD and presence of 
modifiable risk factors (particularly smoking/vaping, obesity, elevated blood pressure), 
linked to local, regional and/or national healthcare electronic databases.  
o Shifting/sharing of tasks from highly trained health professionals to health-care workers, 
particularly community-based health workers, with less training, qualifications, and 
education to facilitate stroke prevention interventions on the individual level.26,64  
Practical example: Effectiveness of population-wide primary prevention strategies in selected 
populations of Finland,60 Japan61 and the USA.62  The validated and free Stroke Riskometer app34,42,43 
which is being used in 19 languages in 78 countries, potentially covering 5.3 billion people; PreventS 
webapp for clinicians.1 Transferring/sharing tasks from highly trained health professionals to health-
care workers was implemented in several areas of India.64,65  
• While governments should provide adequate health services, improve socioeconomic 
conditions, reduce inequities and influence environmental (e.g., air pollution) and lifestyle 
factors (e.g., smoking, vaping, reducing salt, sugar in processed foods and alcohol intake through 
legislation and taxation), health systems should identify, screen, and manage risk factors. 
Revenues from these taxations should be invested into the public health sector and health 
research to improve health of the taxpayers, including appropriate funding of primary prevention 
strategies for stroke/CVD and other NCDs. Governments have to be transparent about the 
proportion of health budgets that are focused on prevention. 
Practical example: Effective smoking cessation campaigns in some countries,66 taxation of sugary 
drinks in several countries, including the UK, Ireland, France, Canada, South Africa, UAE, Portugal, 
Mexico, Sri Lanka,67 junk food taxes in Mexico and Hungary,68 successful alcohol reduction in Russia,69 
successful air pollution campaign in China.70  
• Effectiveness of the proposed primary stroke prevention measures should be regularly assessed 
by monitoring of stroke incidence, mortality, prevalence (rates and absolute numbers) and risk 
factors (prevalence, changes in absolute and relative risks of stroke/CVD) at the individual and 
population levels. 






































Figure 2. Methodological workflow for deriving pragmatic solutions for primary stroke prevention 
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Figure 3. Outline of the PreventS© cloud-based platform for clinicians. PreventS© algorithm for calculation absolute and relative risks of stroke 





Figure 4. Optimal shift in the distribution of cardiovascular disease (CVD) risks through a 
combination of population-wide (including motivational mass individual primary prevention) 
and high CVD risk prevention strategies. Modified from BMJ Glob Health,42 with permission. 
Areas shadowed in  grey show a theoretically possible proportion of the population that 
could benefit from (a) population-wide prevention strategy, (b) high CVD risk prevention 
strategy, and (c) motivational mass individual risk prevention strategy regardless of the CVD 
risk level (i.e., use of mobile applications to reduce lifestyle and other risk factors).  
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Figure 5. Action plan for governments and other policy makers for primary stroke 
prevention measures at the population (socio-economic, environmental, behavioural) and 
individual levels.   
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Table 1: 2021-2030 primary stroke prevention roadmap 
 
Problems Goals Targets Recommendations/Actions Assessment methods 
Lack of funding 





To provide sufficient 
funding for primary 




Encourage all governments and politicians to re-invest revenues from taxation on 
unhealthy products (e.g., tobacco, sugary drinks, alcohol, salt in processed foods, 
aimed at reducing consumption) back to health services and preventative 
strategies 
All health care policy makers should be aware that for every US$1 spent on 
prevention of stroke and CVD there are over US$10 returns on investment. 
Proportion of funding allocated to primary 
stroke prevention.  
Few countries or 
regions have 
established action 
plans for stroke 
prevention. 
To establish country-
specific action plans 
and stroke prevention 
guidelines for every 













All governments should allocate sufficient funding for the development and 
implementation of primary stroke prevention strategies. 
All countries should have financially sustainable action plans for primary and 
secondary stroke prevention. All countries should have culturally appropriate 
guidelines for primary and secondary stroke prevention 
Adults are encouraged to use freely available and validated mobile apps for 
managing their risk factors (e.g., WSO/WHF/WFN/ESO recommended Stroke 
Riskometer app) 
Transferring/sharing tasks of primary stroke prevention from highly trained health 
professionals to health-care workers with less training, qualifications, and 
education, followed by appropriate training. Culturally appropriate education 
about healthy lifestyles should be incorporated into standard education curricula 
and started early in life, with reinforcement across the lifespan. 
Stroke incidence, mortality and disability. 
Prevalence of risk factors. 
5 or 10-year risk of CVD and/or stroke. 
Availability of stroke/TIA and stroke prevention 
clinics and proportion of people at risk of 
stroke and people who have experienced a 
stroke or TIA managed in such clinics.  
Proportion of evidence-based decisions in 
stroke prevention.   
 








different national and 
international agencies 
and organisations 
involved in primary 





Include nationally and internationally recognised stroke experts in all relevant 
national and international agencies and organisations involved in primary 
prevention of NCDs. 
Prioritise primary stroke prevention strategies to reduce exposure to CVD risk 
factors in the whole population across the life course including intrauterine life, 
with a focus on optimal maternal and child health care, behavioural and lifestyle 
risk factors. This would enable an integrative approach that also targets other 
major NCDs, such as dementia, diabetes, cancer, and pulmonary diseases. 
Checklist of representation of stroke experts in 
all relevant national and international agencies 
and organisations involved in primary 




To establish national 
ongoing stroke 
awareness campaigns 
about stroke, its 




All national and regional stroke organisations should conduct ongoing stroke 
awareness campaigns about stroke, its warning signs and prevention, coordinated 
by the WSO. Regular TV programmes is the preferred channel of media for such 
campaigns. 
Stroke awareness surveys. 
Lack of 
monitoring 
To establish national 
and subnational (for 
Whole 
population 
All countries should have monitoring systems to evaluate the effects of primary 
and secondary prevention strategies. 
Changes in the 5- or 10-year absolute risk of 
stroke/CVD of outpatients.  
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systems for 







and people at 
risk of stroke. 
In the absence of sufficient quality country-specific epidemiological data on 
burden of stroke and risk factors, health care policy makers should be encouraged 
to use relevant Global Burden of Disease estimates. 
Regular use of accurate data to support decision-making. 
Strengthening surveillance for key stroke risk 
factors (raised blood pressure, smoking, 
alcohol, obesity, excessive salt consumption) 
with employment of regular (e.g. once in 2-5 
years) inexpensive population-based surveys 
(e.g. WHO STEPS Survey) would provide policy-
makers with accurate estimates of prevalence 
of stroke risk factors to prioritise investments 
to reduce exposure to the risk factors and, 
consequently, reduce incidence and burden of 
stroke. 
Ongoing or regularly (e.g. once in 2-5 years) 
conducted registries of strokes morbidity and 
mortality. 
Insufficient 
funding of stroke 
prevention 




To study determinants 
of stroke occurrence 
and outcomes and the 
best strategies to 





In consultation with recognised regional experts on stroke and public health, 
allocate sufficient funding for research in primary and secondary stroke 
prevention. 
Proportion of research funding allocated to 
primary stroke prevention (compared to the 
total health research funding). 
 




Table 2: Evidence and pragmatic solutions for improving primary stroke prevention worldwide 
 







Ethical, Legal and Social Implications 
(ELSI)/Barriers/ Facilitators 
Recommendation for contextualisation 
and implementation through policy 
makers and other activities 
Countries should have government endorsed policies for community-wide 
stroke prevention.  
Sources: UN/WHO/WSO,3,73-75 Action Plan for Stroke in Europe,76 AHA Guide for 
improving cardiovascular health at the Community Level77 
Level B evidence 
that tobacco, salt, 
and alcohol 




Level A evidence 
for population-
wide primary 
stroke and other 
NCD prevention 
Expertise in 
stroke and CVD 
epidemiology and 
public health.  
Industry lobbing (e.g., for reducing salt 
content in processed food, reducing 
consumption of sugary drinks and 
alcohol). 
 
Major barriers also include lack of: 
(i) expertise to develop an efficient 
action plan. 
(ii) Community support for introducing 
taxation on salt, sugary drinks, 
alcohol, tobacco products. 
(iii) Government and health policy 
engagement; and  
(iv) Public resources for accessible and 
affordable healthy food outlets, 
physical activity facilities, healthy 
ecological environment. 
Policy makers and health experts* to 
develop legislative changes for reducing 
salt content in processed food, reducing 
consumption of sugary drinks and alcohol, 
including the development of policies for 
community-wide stroke prevention 
activities, monitoring effectiveness of these 
activities, and workforce development.  
Reinvestment of taxation revenue into 
primary and secondary prevention, health 
service development and health research. 
Health Ministry order for public health 
services; developing and regularly (at least 
every 5 years) updating national primary 
stroke prevention guidelines.  
Reinvestment of taxation revenue into the 
development of accessible and affordable 
healthy food outlets, physical activity 
facilities, reducing air pollution (healthy 
city). 
Countries should have ongoing stroke awareness and prevention campaigns and 
interventions. 
The main risk factors to be targeted for primary stroke prevention are: elevated 
blood pressure (120/80), low physical activity (<2½ hours a week of moderate 
to vigorous exercise), poor unbalanced diet (e.g. less than 6 servings a day of 
fruits or vegetables), excessive of sodium (>2.3 g/day; equivalent to 5.8 
g/salt/day) intake, overweight (BMI 25 or waist-to-hip ratio 0.8 for women 
and 0.9 for men), tobacco use, cardiac causes (coronary heart disease, AF, 
valve disease, heart failure), dyslipidaemia (total cholesterol 5 mmol/L or 200 
mg/dL; LDL-C 4 mmol/L or 150 mg/dL; HDL-C <1 mmol/L or <40 mg/dL; 
triglycerides >1.7 mmol/L or 150/mg/dL), persistent stress or depression, 
alcohol consumption (>2 standard drink a day in men and >1 standard drink a 
day in women), and diabetes mellitus.  
Level B evidence. 
WHO ‘One 
Health’ initiative  
Level A evidence 
for control of risk 
factors for stroke 
prevention 
Level A evidence 
for use of polypill 











Major barriers include lack of: 
(i) engagement of stakeholders 
(patients, providers, and 
policymakers). 
(ii) collaboration between multiple 
sectors of society (e.g., government, 
public health, research/education). 
 
Policy makers and health experts* to 
develop strategies and action plans for 
ongoing stroke awareness and primary 
prevention, with a strong emphasis in LMIC 
on early detection and management of 
elevated blood pressure, and on reduction 
of exposure to air pollution.  
Policy makers and health experts* should 
develop a plan for prioritising multisectoral 
and cost-effective accessible and 
affordable interventions, including the 
implementation of mobile technologies to 
promote a healthy lifestyle and primary 
 30 
Polypill containing generic BP-lowering medications and statin can be 
recommended for SBP and LDL-C reduction in adults 40-75 years with elevated 
blood pressure (SBP 120-160 mmHg) and LDL-C <190 mg/dL (<4.9 mmol/L), and 
no contraindications to the medications. Pharmacological treatment of 
dyslipidaemia with statins should be considered in adults with LDL-C 190 
mg/dL or at intermediate levels of CVD risk (7.5% 10-year estimated risk). 
Aspirin should not be routinely used for primary stroke prevention. 
Pharmacological treatment of elevated blood pressure for primary stroke 
prevention should be initiated in people with a 10-year CVD risk score 10% or 
an average BP 130/80 mmHg. For those requiring pharmacological therapy, 
the target blood pressure should generally be <130/80 mm Hg. Recreational 
drugs should be avoided. 
All adults should consume a healthy diet that emphasizes the intake of 
vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish 
and minimizes the intake of trans fats, red meat and processed red meats, 
refined carbohydrates, and sweetened beverages. For adults with overweight 
and obesity, counselling and caloric restriction are recommended for achieving 
and maintaining weight loss. Adults should engage in at least 150 minutes per 
week of accumulated moderate-intensity physical activity or 75 minutes per 
week of vigorous-intensity physical activity. Mental health and well-being 
strategies to optimize brain health should be implemented at both the 
individual and societal levels. A life-course approach for healthy lifestyle, 
initiated from maternal and child health, should be exercised.  
Sources: WSO,78 WHO,79 Action Plan for Stroke in Europe,76 Stroke Riskometer 
app,22,34,42,43 AHA stroke/CVD primary prevention guidelines,38,39 European 
Guidelines on CVD prevention,49 INTERSTROKE32 
stroke prevention. For example, 
population-wide strategies recently 
recommended for implementation for 
stroke prevention in all Latin American 
countries (e.g., free Stroke Riskometer 
app), should be one of the priorities for 
funders and policy makers.  
Adequate education and regular antenatal 
care for pregnant women, balanced and 
adequate nutrition for pregnant women 
and infants are important primordial 
measures to reduce the risk of stroke. 
Countries should have a nationwide and representative system for measuring 
and monitoring effects of primary prevention activities (e.g., absolute risk of 
stroke/CVD of the population, stroke incidence and mortality).  
Sources: Action Plan for Stroke in Europe76 









Major barriers include lack of: 
(i) infrastructure to support a 
monitoring programme. 
(ii) expertise to develop an efficient 
programme. 
(iii) capacity to analyse the data 
collected and produce quality 
statistics; and  
(iv) use of data to drive decision-making. 
Policy makers and health experts to 
develop, implement and monitor reliable, 
simple, and fit-for-purpose strategic action 
plan with all stakeholders to ensure the 
availability of a reliable monitoring of 
stroke and risk factors standardised 
surveillance systems in their countries and 
regions.  
*An Ecosystem of all relevant stakeholders and experts for the implementation of the suggested recommendations on primary stroke prevention at the global, 
regional, and national levels is being created to maximise impact of this Policy View paper. AF, atrial fibrillation; AHA, American Heart Association; BMI, body mass 
index; BP, blood pressure; CVD, cardiovascular disease; HDL-C, High density lipoprotein - cholesterol; LDL-C, Low density lipoprotein - cholesterol; NCDs, non-
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